Bristol Myers Squibb (BMY) Total Non-Current Liabilities (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Total Non-Current Liabilities for 18 consecutive years, with $61.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 15.6% year-over-year to $61.0 billion in Q2 2026; TTM through Jun 2026 was $61.0 billion, a 15.6% decrease from a year earlier, with the FY2025 full-year figure at $66.5 billion, down 7.33% from the prior year.
• Total Non-Current Liabilities was $61.0 billion for Q2 2026 at Bristol Myers Squibb, down from $61.5 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $75.8 billion in Q1 2024 and troughed at $55.6 billion in Q2 2023.
• A 5-year average of $64.8 billion and a median of $62.8 billion in 2022 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 35.92% in 2024 and decreased 15.6% in 2026, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $59.1 billion in 2022, then grew by 0.24% to $59.3 billion in 2023, then gained by 21.08% to $71.7 billion in 2024, then slipped by 7.33% to $66.5 billion in 2025, then slipped by 8.3% to $61.0 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $61.0 billion (Q2 2026), $61.5 billion (Q1 2026), and $66.5 billion (Q4 2025), per Business Quant data.